Mineralys Therapeutics, Inc. (MLYS) Stock Price & Growth Analysis - Tweevest

New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out

Mineralys Therapeutics, Inc.

MLYS

NASDAQ

Unprofitable

EPS improving

Unprofitable

EPS improving

891M

Biotechnology

Next Earning date - 12 Aug 2025

891M

Biotechnology

Next Earning date - 12 Aug 2025

13.66USD

-0.48 ( -3.43%)

Market Closed (as of Aug 01, 20:00 EDT)

Relative Strenght

23

Volume Buzz

26%

Earning Acce

Yes

Dist 52w H.

26%

Quote Panel

Updated August 3, 2025

1W 0.51 % 1M 1.03 % 3M -12.54 % 1Y 22.49 %

Key Metrics

Market Cap
890.62M
Shares Outstanding
65.18M
Share in Float
40.63M
Dividende
0

Earning Date
12 Aug 2025
Price Target
13.665
Average Volume
801598
Beta
-0.306

Range
8.241-18.38
Industry
Biotechnology
Website
https://mineralystx.com
Sector
Healthcare

Fundamentals

Relative Strength

MLYS

Sector

loading...

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Forecast

$8M

NaN%

2026-Revenue

$3.13

-297%

2026-EPS

0

Analyst rating

Strong Sell

Sell

Buy

Neutral

Strong Buy

Buy

Price Target

48.00(251.26%)

Number of analyst

1

Last analyst upgrade/downgrade

Jefferies

initialise

Previous: Not converted

2025-06-10

Now: Hold

H.C. Wainwright

initialise

Previous: Not converted

2024-07-10

Now: Buy

Goldman Sachs

initialise

Previous: Not converted

2024-04-02

Now: Buy

Earnings Growth

YoY

Current

Estimates

Q2.23

N/A

-0.31
vs -0.35

Q3.23

N/A

-0.57
vs -1288.84

Q4.23

N/A

-0.61
vs -1.74

Q1.24

N/A

-0.70
vs -0.51

Q2.24

N/A

-0.83
vs -0.31

Q3.24

N/A

-1.13
vs -0.57

Q4.24

N/A

-0.98
vs -0.61

Q1.25

N/A

-0.79
vs -0.70

Q2.25

N/A

-0.74
vs -0.83

Q3.25

N/A

-0.73
vs -1.13

Sales Growth

YoY

Current

Estimates

Q4.22

NA

NA vs NA

Q1.23

NA

NA vs NA

Q2.23

NA

NA vs NA

Q3.23

NA

NA vs NA

Q4.23

NA

NA vs NA

Q1.24

NA

NA vs NA

Q2.24

NA

NA vs NA

Q3.24

NA

NA vs NA

Q4.24

NA

NA vs NA

Q1.25

NA

NA vs NA

Return on Equity

QoQ

Q2.23

-4%

-0.04
vs -0.04

Q3.23

-9%

-0.09
vs -0.04

Q4.23

-10%

-0.10
vs -0.09

Q1.24

-10%

-0.10
vs -0.10

Q2.24

-14%

-0.14
vs -0.10

Q3.24

-24%

-0.24
vs -0.14

Q4.24

-26%

-0.26
vs -0.24

Q1.25

-12%

-0.12
vs -0.26

Institutionnal Ownership

QoQ

Q1.23

66

66
vs NA

NA

Q2.23

68

68
vs 66

3%

Q3.23

77

77
vs 68

13%

Q4.23

88

88
vs 77

14%

Q1.24

94

94
vs 88

7%

Q2.24

95

95
vs 94

1%

Q4.24

107

107
vs NA

NA

Q1.25

160

160
vs 107

50%

Earnings Growth

Latest News

MLYS

globenewswire.com

4 hours ago

Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025)

MLYS

globenewswire.com

7 hours ago

Mineralys Therapeutics Announces Positive Topline Results from Phase 2 Explore-CKD Trial of Lorundrostat for the Treatment of Hypertension in Subjects with CKD and Albuminuria

MLYS

zacks.com

9 hours ago

Here's Why Momentum in Mineralys Therapeutics, Inc. (MLYS) Should Keep going

MLYS

zacks.com

10 hours ago

Does Mineralys Therapeutics, Inc. (MLYS) Have the Potential to Rally 154.21% as Wall Street Analysts Expect?

MLYS

globenewswire.com

11 hours ago

Mineralys Therapeutics Announces Journal of the American Medical Association (JAMA) Publication of Pivotal Phase 3 Launch-HTN Trial for Lorundrostat

MLYS

zacks.com

13 hours ago

Mineralys Therapeutics, Inc. (MLYS) Upgraded to Buy: Here's Why